Evidence map›Paper›PMID 26660146›Full record

ReviewHormones & cancer2016

5th International ACC Symposium: Old Syndromes with New Biomarkers and New Therapies with Old Medications.

Sarika N Rao, Mouhammed Amir Habra

Abstract readReview
In one paragraph

Review in Hormones & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sarika N RaoDepartment of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030, TX, USA.
Mouhammed Amir HabraDepartment of Endocrine Neoplasia and Hormonal Disorders, Unit 1461, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, 77030, TX, USA. mahabra@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with variable but often aggressive clinical course. Hormonal overproduction can be seen in about half of all ACC cases. When present, the hormonal excess leads to a wide range of metabolic, musculoskeletal, cardiovascular, and infectious complications and adds multiple layers of complexity to the management of ACC. To improve the outcome of patients with hormonally functioning ACC, an effective approach should include parallel efforts to achieve oncologic and hormonal control. An experienced multidisciplinary team is crucial to deliver and coordinate care to manage the specific aspects of this condition. In this review, we summarized the clinical features and management of hormonally functioning ACCs to assist practicing physicians in addressing the complex medical issues that can be seen in the context of this clinical entity.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAntineoplastic AgentsBiomarkers, TumorCongresses as TopicHormonesHumansTreatment OutcomeAntineoplastic AgentsBiomarkers, TumorHormones

Identifiers

PMID26660146
PMCPMC10355959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.